CN1244801A - 用于糖尿病的磺酰脲类－格列酮类协同联合给药 - Google Patents

用于糖尿病的磺酰脲类－格列酮类协同联合给药 Download PDF

Info

Publication number
CN1244801A
CN1244801A CN97181434A CN97181434A CN1244801A CN 1244801 A CN1244801 A CN 1244801A CN 97181434 A CN97181434 A CN 97181434A CN 97181434 A CN97181434 A CN 97181434A CN 1244801 A CN1244801 A CN 1244801A
Authority
CN
China
Prior art keywords
patient
troglitazone
glibenclamide
baseline
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN97181434A
Other languages
English (en)
Chinese (zh)
Inventor
R·W·惠特科姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1244801A publication Critical patent/CN1244801A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN97181434A 1997-02-19 1997-12-01 用于糖尿病的磺酰脲类－格列酮类协同联合给药 Pending CN1244801A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
US60/038,224 1997-02-19

Publications (1)

Publication Number Publication Date
CN1244801A true CN1244801A (zh) 2000-02-16

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97181434A Pending CN1244801A (zh) 1997-02-19 1997-12-01 用于糖尿病的磺酰脲类－格列酮类协同联合给药

Country Status (29)

Country Link
US (2) US5859037A (https=)
EP (1) EP0957923A1 (https=)
JP (1) JP2001512478A (https=)
KR (1) KR20000071179A (https=)
CN (1) CN1244801A (https=)
AR (1) AR011829A1 (https=)
AU (1) AU741215B2 (https=)
BG (1) BG103671A (https=)
BR (1) BR9714505A (https=)
CA (1) CA2272478A1 (https=)
CZ (1) CZ289299A3 (https=)
EA (1) EA199900725A1 (https=)
EE (1) EE9900345A (https=)
GT (1) GT199800037A (https=)
HN (1) HN1997000167A (https=)
HU (1) HUP0001528A3 (https=)
IL (1) IL130027A (https=)
IS (1) IS5058A (https=)
NO (1) NO993982D0 (https=)
NZ (1) NZ336002A (https=)
PA (1) PA8447401A1 (https=)
PE (1) PE74399A1 (https=)
PL (1) PL335166A1 (https=)
SK (1) SK111899A3 (https=)
SV (1) SV1998000010A (https=)
TR (1) TR199902033T2 (https=)
UY (1) UY24893A1 (https=)
WO (1) WO1998036755A1 (https=)
ZA (1) ZA981343B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086980A1 (zh) * 2011-12-14 2013-06-20 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
CN107320732A (zh) * 2008-12-04 2017-11-07 于崇曦 高穿透性组合物及其应用
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
KR20060105005A (ko) * 1997-06-18 2006-10-09 스미스클라인비이참피이엘시이 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
BR9810142A (pt) * 1997-06-18 2000-08-08 Smithkline Beecham Plc Tratamento de diabete com tiazolidinadiona e sulfonil-uréia
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
PL352756A1 (en) * 1998-12-24 2003-09-08 Metabasis Therapeutics, Inc. A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
DE60035163T2 (de) * 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) * 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
AU2003272504A1 (en) 2002-09-20 2004-04-08 Andrx Labs Llc Multistage formulation containing a biguanide and thiazolidindione derivatives
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
CA2540225C (en) 2003-10-31 2012-03-06 Takeda Pharmaceutical Company Limited Solid preparation of pioglitazone, glimepiride and a polyoxyethylene sorbitan fatty acid ester
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
CA2622069A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
CA2623412A1 (en) * 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
ES2638977T3 (es) 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
CN102655866B (zh) * 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
US9241952B2 (en) 2010-05-24 2016-01-26 Ozstar Therapeutics Pty Ltd Method of treating type II diabetes, hyperglycemia or hypoglycemia by administering a synergistic combination of a sulphonylurea and inulin
CN103582463B (zh) 2011-01-19 2018-02-13 弗拉克泰尔实验室公司 用于组织处理的装置与方法
KR102104384B1 (ko) 2011-11-23 2020-04-27 오즈스타 테라피우틱스 피티와이 엘티디 개선된 상승작용성 항-당뇨병성 조성물
AU2013226062B2 (en) 2012-02-27 2017-10-19 Fractyl Health, Inc. Heat ablation systems, devices and methods for the treatment of tissue
EP2838598B1 (en) 2012-04-19 2020-01-15 Fractyl Laboratories, Inc. Tissue expansion devices
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
EP3071286B1 (en) 2013-11-22 2024-01-03 Fractyl Health, Inc. Systems for the creation of a therapeutic restriction in the gastrointestinal tract
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
WO2016011269A1 (en) * 2014-07-16 2016-01-21 Fractyl Laboratories, Inc. Methods and systems for treating diabetes and related diseases and disorders
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
US12274703B2 (en) 2017-12-21 2025-04-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US12350264B2 (en) 2019-11-22 2025-07-08 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder
EP4090282A4 (en) 2020-01-15 2024-02-21 Fractyl Health, Inc. AUTOMATIC FABRIC TREATMENT DEVICES, SYSTEMS AND METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IL118778A (en) * 1995-07-03 1999-07-14 Sankyo Co Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107320732A (zh) * 2008-12-04 2017-11-07 于崇曦 高穿透性组合物及其应用
US11541029B2 (en) 2008-12-04 2023-01-03 Techfields Pharma Co., Ltd. High penetration compositions and their applications
WO2013086980A1 (zh) * 2011-12-14 2013-06-20 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法

Also Published As

Publication number Publication date
PE74399A1 (es) 1999-08-20
EA199900725A1 (ru) 2000-04-24
SK111899A3 (en) 2000-09-12
AR011829A1 (es) 2000-09-13
AU5590898A (en) 1998-09-09
HN1997000167A (es) 1999-02-09
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
EE9900345A (et) 2000-02-15
IS5058A (is) 1999-05-27
TR199902033T2 (xx) 2000-02-21
CZ289299A3 (cs) 1999-11-17
ZA981343B (en) 1998-11-16
CA2272478A1 (en) 1998-08-27
US5972973A (en) 1999-10-26
IL130027A0 (en) 2000-02-29
BR9714505A (pt) 2000-03-21
UY24893A1 (es) 1998-07-10
HUP0001528A3 (en) 2000-12-28
AU741215B2 (en) 2001-11-29
PA8447401A1 (es) 2001-12-14
JP2001512478A (ja) 2001-08-21
NZ336002A (en) 2002-03-28
WO1998036755A1 (en) 1998-08-27
PL335166A1 (en) 2000-04-10
SV1998000010A (es) 1999-02-02
NO993982L (no) 1999-08-18
IL130027A (en) 2005-09-25
EP0957923A1 (en) 1999-11-24
US5859037A (en) 1999-01-12
KR20000071179A (ko) 2000-11-25
NO993982D0 (no) 1999-08-18
BG103671A (en) 2000-04-28

Similar Documents

Publication Publication Date Title
CN1244801A (zh) 用于糖尿病的磺酰脲类－格列酮类协同联合给药
CN1165310C (zh) 含有(e)-7-[4-(4-氟苯基)-6-异丙基-2-[甲基(甲基磺酰基)氨基]嘧啶-5基](3r,(5s)-3,5-二羟基庚-6-烯酸以及p450同工酶3a4的抑制剂,诱导剂或底物的药物组合物)
CN1202823C (zh) 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病的发作
CN1091006A (zh) 用作降血糖药和治疗早老性痴呆症的化合物
CN1703424A (zh) Glp－1衍生物及其经粘膜吸收的制剂
CN1751038A (zh) 作为葡萄糖代谢调节剂的经取代芳基和杂芳基衍生物及葡萄糖代谢失调的预防和治疗
CN1511038A (zh) 含有葡萄糖重吸收抑制剂和维生素a类-x受体调节剂的联合治疗
CN1571676A (zh) Glp－1和胰岛素的双相混合物
CN1720042A (zh) DPP－IV抑制剂与PPAR－α化合物的组合
CN1568190A (zh) 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法
CN1596103A (zh) 用于治疗ii型糖尿病、包含二甲双胍和格列本脲的药物组合物
CN1236769C (zh) 抑制细胞粘着的抑制剂
CN1652788A (zh) 治疗糖尿病的方法
CN1382440A (zh) 用于治疗抑郁症或预防认知功能退化的方法和药盒
CN1307989C (zh) 植烷酸在制备治疗糖尿病的药物中的用途
CN1557352A (zh) 菊苣水提取物的新用途
CN1294936C (zh) 一种治疗糖尿病的药物及其制备方法
HK1024180A (en) Sulfonylurea-glitazone synergistic combinations for diabetes
CN1798735A (zh) 用作激素敏感性脂肪酶的抑制剂的1－芳基－4－(芳氧基羰基)－哌嗪衍生物
CN1491719A (zh) 蝉花在制备治疗慢性肾功能衰竭的药物中的应用
CN1294925C (zh) 一种治疗高血压和高血脂的中药及其制备方法
CN85107521A (zh) 改进的抗炎药物配方的制备方法
CN1372476A (zh) 药物组合物
CN1615888A (zh) 一种药物组合物及其用途
CN1622945A (zh) 噻唑烷二酮衍生物以及包含该衍生物的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1024180

Country of ref document: HK